Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Galenica AG is a leading fully integrated healthcare provider in Switzerland, operating as a holding company headquartered in Bern since its founding in 1927 by 16 pharmacists seeking collective purchasing power. It manages an extensive network of over 500 pharmacies under brands like Amavita and Coop Vitality through its Products & Care segment, delivering retail healthcare services, own-brand products, and on-site health tests to patients and customers. The Logistics & IT segment handles pre-wholesale distribution, pharmaceutical logistics, healthcare data management, and digital pharmacy support systems, serving pharmacies, hospitals, insurers, and pharmaceutical companies. Group Services oversee central operations. With nearly 8,000 employees, Galenica AG reported CHF 3.9 billion in net sales in 2024, underscoring its pivotal role in Switzerland's pharmaceutical supply chain. Key milestones include its 1932 renaming and headquarters relocation to Bern, the 2017 split from Vifor Pharma to sharpen focus on Swiss healthcare, and innovations like the 2025 Prescription Manager. The company emphasizes sustainability, personalized care, and seamless end-to-end solutions across physical and digital infrastructure.
Operating margin is thin at 5.47%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.5%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
CHF 4.14B
▲ +5.5% YoY
Net Income (TTM)
CHF 182M
▼ -0.7% YoY
Op. Margin
5.47%
▲ +0.3pp YoY
ROIC
10.64%
▲ +0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
CHF 244M
▲ +26.9% YoY
Op. Cash Flow (TTM)
CHF 271M
▲ +20.4% YoY
Net Debt
CHF 128M
Cash & Equiv.
CHF 116M
3Y CAGR: +4.8%
3Y CAGR: +13.5%
Continue Research